Disease Info Card

Endometrial Carcinoma

Information about Endometrial Carcinoma: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Endometrial Carcinoma

Most recent studies have shown that Endometrial Carcinoma shares some biological mechanisms with adenocarcinoma, carcinoma, carcinoma-endometrioid, cell-invasion, endometrial-adenocarcinoma, endometrial-hyperplasia, endometrial-neoplasms, endometrial-polyp, hemorrhage, hyperplasia, malignant-neoplasm-of-breast, malignant-neoplasm-of-ovary, malignant-neoplasms, malignant-paraganglionic-neoplasm, malignant-tumor-of-cervix, mammary-neoplasms, neoplasm-metastasis, neoplasms, ovarian-neoplasm, uterine-neoplasms.

Among the many pathways, these few ones have gauged particular interests from scientists studying Endometrial Carcinoma, and have been seen in publications frequently: Aging, Angiogenesis, Cell Adhesion, Cell Cycle, Cell Cycle Arrest, Cell Death, Cell Differentiation, Cell Growth, Cell Proliferation, Coagulation, Induction Of Apoptosis, Localization, Menarche, Menopause, Menstruation, Methylation, Mismatch Repair, Ovulation, Pathogenesis, Secretion

Quite a number of genes have been found to play important roles in Endometrial Carcinoma, such as AKT1, BCL2, CDKN1A, CYP19A1, DBT, EGF, EGFR, ERBB2, ESR1, MID1, MLH1, MSH2, MSH6, MUC16, PGR, PTEN, TMEM37, TP53, VEGFA. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.